TY - JOUR AU - Nisa, Lluís AU - Häfliger, Pascal AU - Poliaková, Michaela AU - Giger, Roland AU - Francica, Paola AU - Aebersold, Daniel Matthias AU - Charles, Roch-Philippe AU - Zimmer, Yitzhak AU - Medová, Michaela PY - 2017 DA - 2017/05/22 TI - PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models JO - Molecular Cancer SP - 93 VL - 16 IS - 1 AB - The MET receptor tyrosine kinase represents a promising target in cancer. PIK3CA activating mutations are common in several tumor types and can potentially confer resistance to anti-receptor tyrosine kinase therapy. SN - 1476-4598 UR - https://doi.org/10.1186/s12943-017-0660-5 DO - 10.1186/s12943-017-0660-5 ID - Nisa2017 ER -